| In patients with atopic dermatitis, plasma concentrations of ruxolitinib were minimal following topical application of ruxolitinib cream. Consistent with this observation, systemic adverse events commonly associated with oral JAK inhibitors were not observed. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.